La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
Cogent Biosciences Gestione
Gestione criteri di controllo 2/4
Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.
Informazioni chiave
Andy Robbins
Amministratore delegato
US$7.9m
Compenso totale
| Percentuale dello stipendio del CEO | 8.3% |
| Mandato del CEO | 3.9yrs |
| Proprietà del CEO | n/a |
| Durata media del management | 3.6yrs |
| Durata media del Consiglio di amministrazione | 4.2yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Cogent Biosciences (NASDAQ:COGT) Is In A Good Position To Deliver On Growth Plans
Sep 04
Cogent Biosciences: Inflection Year Directly Ahead
Jun 23Cogent Biosciences (NASDAQ:COGT) Is In A Good Position To Deliver On Growth Plans
May 22Cogent Biosciences: Stock Soars On Cash Injection Ahead Of Major Data Catalyst
Feb 14Here's Why We're Watching Cogent Biosciences' (NASDAQ:COGT) Cash Burn Situation
Nov 27Is Cogent Biosciences (NASDAQ:COGT) In A Good Position To Invest In Growth?
Jun 20Here's Why We're Not Too Worried About Cogent Biosciences' (NASDAQ:COGT) Cash Burn Situation
Mar 05Here's Why We're Not Too Worried About Cogent Biosciences' (NASDAQ:COGT) Cash Burn Situation
Nov 18Cogent Biosciences: What's Ahead
Sep 13Cogent Biosciences: APEX Data Was Interesting, But We Need More
Jun 26Is Cogent Biosciences (NASDAQ:COGT) In A Good Position To Invest In Growth?
Jun 10Cogent Biosciences names new chief legal officer
May 03What You Need To Know About Cogent Biosciences, Inc.'s (NASDAQ:COGT) Investor Composition
Mar 17Cogent Biosciences gets Piper Sandler nod on Kiq acquisition
Dec 23Cogent Biosciences prices upsized $100M equity offering
Dec 02Cogent Bio launches $60M equity offering, shares down 7%
Nov 30Cogent Bio reports data from PLX9486 combo trial in GIST patients
Nov 18Cogent Biosciences EPS misses by $4.91
Nov 09Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Guadagni aziendali |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$227m |
| Mar 31 2024 | n/a | n/a | -US$212m |
| Dec 31 2023 | US$8m | US$656k | -US$192m |
| Sep 30 2023 | n/a | n/a | -US$178m |
| Jun 30 2023 | n/a | n/a | -US$157m |
| Mar 31 2023 | n/a | n/a | -US$148m |
| Dec 31 2022 | US$4m | US$624k | -US$140m |
| Sep 30 2022 | n/a | n/a | -US$126m |
| Jun 30 2022 | n/a | n/a | -US$110m |
| Mar 31 2022 | n/a | n/a | -US$91m |
| Dec 31 2021 | US$3m | US$593k | -US$72m |
| Sep 30 2021 | n/a | n/a | -US$163m |
| Jun 30 2021 | n/a | n/a | -US$194m |
| Mar 31 2021 | n/a | n/a | -US$185m |
| Dec 31 2020 | US$18m | US$102k | -US$179m |
Compensazione vs Mercato: La retribuzione totale di Andy ($USD 7.90M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 3.30M ).
Compensazione vs guadagni: La retribuzione di Andy è aumentata nonostante l'azienda non sia redditizia.
AMMINISTRATORE DELEGATO
Andy Robbins (48 yo)
3.9yrs
Mandato
US$7,898,772
Compensazione
Mr. Andrew R. Robbins, also known as Andy, M.B.A., serves as Chief Executive Officer, President and Director at of Cogent Biosciences, Inc. (formerly Unum Therapeutics Inc.) since October 23, 2020. He was...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| President | 3.9yrs | US$7.90m | Nessun dato | |
| Chief Scientific Officer | 3.4yrs | US$2.98m | 0% $ 0 | |
| Chief Medical Officer | 5.3yrs | US$3.00m | 0.0012% $ 14.1k | |
| CFO & Principal Accounting Officer | 4.2yrs | US$2.14m | Nessun dato | |
| Chief Technology Officer | 3.8yrs | Nessun dato | Nessun dato | |
| Senior Director of Investor Relations | no data | Nessun dato | Nessun dato | |
| Chief Legal Officer & Corporate Secretary | 3.3yrs | Nessun dato | Nessun dato | |
| Chief People Officer | no data | Nessun dato | Nessun dato | |
| Senior VP of Medical Affairs & Chief Patient Officer | no data | Nessun dato | Nessun dato | |
| Senior Vice President of Chemistry | no data | Nessun dato | Nessun dato | |
| VP & Head of Clinical Development | 1.8yrs | Nessun dato | Nessun dato | |
| Senior VP and Head of Regulatory & Pharmacovigilance | less than a year | Nessun dato | Nessun dato |
3.6yrs
Durata media
48yo
Età media
Gestione esperta: Il team dirigenziale di COGT è considerato esperto (durata media dell'incarico 3.5 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| President | 3.9yrs | US$7.90m | Nessun dato | |
| Independent Director | 5.2yrs | US$345.49k | 0% $ 0 | |
| Independent Director | 5.2yrs | US$336.69k | 0% $ 0 | |
| Independent Director | 3.6yrs | US$345.80k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Independent Director | 6.6yrs | US$340.37k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Member of Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Independent Director | 4.2yrs | US$341.36k | 0% $ 0 | |
| Independent Chairman of the Board | 4.2yrs | US$364.55k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Member of Scientific Advisory Board | 1.7yrs | Nessun dato | Nessun dato |
4.2yrs
Durata media
58yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di COGT sono considerati esperti (durata media dell'incarico 4.1 anni).